@article{MTMT:30362752,
	title = {Experiences with fecal microbiota transplantation in Clostridium difficile infections via upper gastrointestinal tract},
	url = {https://m2.mtmt.hu/api/publication/30362752},
	author = {Vigvári, Szabolcs József and Vincze, Áron and Solt, Jenő and Sipos, Dávid and Feiszt, Zsófia and Kovács, Beáta and Kappéter, Ágnes and Péterfi, Zoltán},
	doi = {10.1556/030.65.2018.051},
	journal-iso = {ACTA MICROBIOL IMMUNOL HUNG},
	journal = {ACTA MICROBIOLOGICA ET IMMUNOLOGICA HUNGARICA},
	volume = {66},
	unique-id = {30362752},
	issn = {1217-8950},
	abstract = {Dramatic changes in the epidemiology of Clostridium difficile infections have been reported from the western world in the past decade. The proportion of severe cases is significantly elevating and clinicians now have to contend with the problem of additional and more frequent episodes of recurrences including an upward trend in the mortality rate. This situation led us to investigate the possibility of the fecal microbiota transplantation (FMT). An amount of 100 ml of fecal microbiota solution was instilled into a nasojejunal (NJ) tube in 16 cases and into a nasogastric (NG) tube in 44 cases. In all of the cases, where the solution was instilled via nasojejunal tubes, the symptoms resolved within 24 h. We did not note any recurrences in this group. When the material was flushed in through nasogastric tubes, the symptoms resolved in 39 (88.64%) cases within 24 h. In this group, we have experienced a recurrent episode of C. difficile infection in five (11.36%) cases. Three of them were cured with a second transplantation. We have found that in our practice the upper gastrointestinal tract methods had the primary cure rate of 91.67%, whereas the secondary cure rate is 96.67%. When we compared the NJ and NG methods, we have found that the differences in the outcomes are not significant statistically (p = 0.3113 using Fisher's exact probability test). In conclusion, FMT proved to be very effective, particularly in recurrent infections and in cases where conventional treatment had failed.},
	keywords = {nasojejunal tube; FECAL MICROBIOTA TRANSPLANTATION; nasogastric tube},
	year = {2019},
	eissn = {1588-2640},
	pages = {179-188},
	orcid-numbers = {Vincze, Áron/0000-0003-2217-7686; Péterfi, Zoltán/0000-0001-9658-153X}
}

@article{MTMT:3304835,
	title = {Faecal microbiota transplantation for Clostridium difficile infection using a lyophilized inoculum from non-related donors: A case series involving 19 patients},
	url = {https://m2.mtmt.hu/api/publication/3304835},
	author = {Vigvári, Szabolcs József and Sipos, Dávid and Solt, Jenő and Vincze, Áron and Kocsis, Béla and Nemes, Zsuzsanna and Kappéter, Ágnes and Feiszt, Zsófia and Kovács, Beáta and Péterfi, Zoltán},
	doi = {10.1556/030.64.2017.042},
	journal-iso = {ACTA MICROBIOL IMMUNOL HUNG},
	journal = {ACTA MICROBIOLOGICA ET IMMUNOLOGICA HUNGARICA},
	volume = {66},
	unique-id = {3304835},
	issn = {1217-8950},
	abstract = {Faecal microbiota transplantation (FMT) has been reported to be effective in treating relapsing of refractory Clostridium difficile infections, although some practical barriers are limiting its widespread use. In this study, our objective was to evaluate the rate of resolution of diarrhea following administration of lyophilized and resolved FMT via a nasogastric (NG) tube. We recruited 19 patients suffered from laboratory-confirmed C. difficile infection. Each of them was treated by lyophilized and resolved inoculum through a NG tube. One participant succumbed following the procedure due to unrelated diseases. Out of 18 cases, 15 patients reportedly experienced a resolution of the symptoms. One patient was treated with another course of antibiotics, and two of the non-responders were successfully retreated with another course of FMT utilizing a lyophilized inoculum. Notably, no significant adverse activities were observed. In accordance to our clinical experiences, a patient will likely benefit from FMT treatment including lyophilized inoculum.},
	year = {2019},
	eissn = {1588-2640},
	pages = {69-78},
	orcid-numbers = {Vincze, Áron/0000-0003-2217-7686; Péterfi, Zoltán/0000-0001-9658-153X}
}

@article{MTMT:3360067,
	title = {Risk factors for Clostridium difficile infections in Baranya County, Southern Hungary},
	url = {https://m2.mtmt.hu/api/publication/3360067},
	author = {Vigvári, Szabolcs József and Sipos, Dávid and Kappéter, Ágnes and Feiszt, Zsófia and Kovács, Beáta and Péterfi, Zoltán},
	doi = {10.1556/030.65.2018.023},
	journal-iso = {ACTA MICROBIOL IMMUNOL HUNG},
	journal = {ACTA MICROBIOLOGICA ET IMMUNOLOGICA HUNGARICA},
	volume = {65},
	unique-id = {3360067},
	issn = {1217-8950},
	abstract = {In the past decade, Clostridium difficile infections (CDIs) have become a major public health challenge. Their epidemiology has radically changed with a significant rise in the number of cases and an increase in severe episodes. Recurrence and failure of conventional treatments are very common. Furthermore, a spread of CDI has emerged in general population without the usual risk factors (unexposed to antibiotic treatment, young people, etc.). The conventional treatments (metronidazole and vancomycin) are still effective and are the first-line antibiotics with new recommendations. New therapeutic strategies are now available. Recent studies show a better efficacy of vancomycin compared with metronidazole for severe episodes. Fidaxomicin is a novel antibiotic drug with an efficacy similar to vancomycin and a lower risk of recurrence. Finally, for relapsing forms, fecal microbiota transplantation (FMT) seems to be the best option. We determined risk factors for CDI among patients treated at the infectious diseases ward of our hospital in Pecs. The study included 886 patients with CDI from 2009 to 2014. The average number of recurrent episodes was 2.16 and the proportion of severe cases was 66%. Among our patients, 726 (82%) had taken antibiotics and 769 (86.8%) had been hospitalized in the prior 3 months before developing CDI. We have found that prior statin use could be a significant risk factor of CDI (OR: 1.7765, 95% CI: 1.3966-2.2597, p < 0.0001). Finally, we present the comparative efficacy of different types of treatment (metronidazole, vancomycin, fidaxomicin, and FMT).},
	year = {2018},
	eissn = {1588-2640},
	pages = {183-192},
	orcid-numbers = {Péterfi, Zoltán/0000-0001-9658-153X}
}

@article{MTMT:3341070,
	title = {Characterization of Asymptomatic Bacteriuria Escherichia coli Isolates in Search of Alternative Strains for Efficient Bacterial Interference against Uropathogens},
	url = {https://m2.mtmt.hu/api/publication/3341070},
	author = {Stork, C and Kovács, Beáta and Rózsai, Barnabás and Putze, J and Kiel, M and Dorn, Ágnes and Kovács, Judit Klára and Melegh, Szilvia Zsóka and Leimbach, A and Kovács, Tamás and Schneider, György and Kerényi, Mónika and Emődy, Levente and Dobrindt, U},
	doi = {10.3389/fmicb.2018.00214},
	journal-iso = {FRONT MICROBIOL},
	journal = {FRONTIERS IN MICROBIOLOGY},
	volume = {9},
	unique-id = {3341070},
	issn = {1664-302X},
	abstract = {Asymptomatic bacterial colonization of the urinary bladder (asymptomatic bacteriuria, ABU) can prevent bladder colonization by uropathogens and thus symptomatic urinary tract infection (UTI). Deliberate bladder colonization with Escherichia coli ABU isolate 83972 has been shown to outcompete uropathogens and prevent symptomatic UTI by bacterial interference. Many ABU isolates evolved from uropathogenic ancestors and, although attenuated, may still be able to express virulence-associated factors. Our aim was to screen for efficient and safe candidate strains that could be used as alternatives to E. coli 83972 for preventive and therapeutic bladder colonization. To identify ABU E. coli strains with minimal virulence potential but maximal interference efficiency, we compared nine ABU isolates from diabetic patients regarding their virulence-and fitness-associated phenotypes in vitro, their virulence in a murine model of sepsis and their genome content. We identified strains in competitive growth experiments, which successfully interfere with colonization of ABU isolate 83972 or uropathogenic E. coli strain 536. Six isolates were able to outcompete E. coli 83972 and two of them also outcompeted UPEC 536 during growth in urine. Superior competitiveness was not simply a result of better growth abilities in urine, but seems also to involve expression of antagonistic factors. Competitiveness in urine did not correlate with the prevalence of determinants coding for adhesins, iron uptake, toxins, and antagonistic factors. Three ABU strains (isolates 61, 106, and 123) with superior competitiveness relative to ABU model strain 83972 display low in vivo virulence in a murine sepsis model, and susceptibility to antibiotics. They belong to different phylogroups and differ in the presence of ExPEC virulence-and fitness-associated genes. Importantly, they all lack marked cytotoxic activity and exhibit a high LD50 value in the sepsis model. These strains represent promising candidates for a more detailed assessment of relevant fitness traits in urine and their suitability for therapeutic bladder colonization.},
	keywords = {URINE; GENES; Virulence; Escherichia coli; pathogenicity; IMPACT; PREVENTION; Bladder; competitiveness; asymptomatic bacteriuria; fitness; URINARY-TRACT-INFECTION; Comparative genomics; FIMBRIAE; STRAIN-83972; PHYLOGENETIC GROUP B2; whole genome draft sequences; bacterial interference},
	year = {2018},
	eissn = {1664-302X},
	orcid-numbers = {Rózsai, Barnabás/0000-0002-8401-5415; Kerényi, Mónika/0000-0002-5767-9662}
}

@article{MTMT:3317813,
	title = {Whole-Genome Draft Sequences of Nine Asymptomatic Escherichia coli Bacteriuria Isolates from Diabetic Patients.},
	url = {https://m2.mtmt.hu/api/publication/3317813},
	author = {Stork, C and Kovács, Beáta and Trost, E and Kovács, Tamás and Schneider, György and Rózsai, Barnabás and Kerényi, Mónika and Emődy, Levente and Dobrindt, U},
	doi = {10.1128/genomeA.01369-17},
	journal-iso = {GENOME ANNOUNC},
	journal = {GENOME ANNOUNCEMENTS},
	volume = {6},
	unique-id = {3317813},
	abstract = {Escherichia coli can colonize the urinary bladder without causing a disease response in the host. This asymptomatic bacteriuria (ABU) can protect against recurrent symptomatic urinary tract infection by virulent bacteria. Here, we report the whole-genome sequences of nine E. coli ABU isolates from diabetic patients.},
	year = {2018},
	eissn = {2169-8287},
	orcid-numbers = {Rózsai, Barnabás/0000-0002-8401-5415; Kerényi, Mónika/0000-0002-5767-9662}
}

@article{MTMT:2798567,
	title = {Faecal microbiota transplantation in Clostridium difficile infections},
	url = {https://m2.mtmt.hu/api/publication/2798567},
	author = {Vigvári, Szabolcs József and Nemes, Zsuzsanna and Vincze, Áron and Solt, Jenő and Sipos, Dávid and Feiszt, Zsófia and Kovács, Beáta and Bartos, Barbara and Péterfi, Zoltán},
	doi = {10.3109/00365548.2014.969305},
	journal-iso = {INFECT DIS-NOR},
	journal = {INFECTIOUS DISEASES},
	volume = {47},
	unique-id = {2798567},
	issn = {2374-4235},
	year = {2015},
	eissn = {2374-4243},
	pages = {114-116},
	orcid-numbers = {Vincze, Áron/0000-0003-2217-7686; Péterfi, Zoltán/0000-0001-9658-153X}
}

@article{MTMT:2765530,
	title = {Clostridium difficile-fertőzések széklettranszplantációval való kezelése során nyert tapasztalataink},
	url = {https://m2.mtmt.hu/api/publication/2765530},
	author = {Vigvári, Szabolcs József and Nemes, Zsuzsanna and Vincze, Áron and Solt, J and Sipos, Dávid and Feiszt, Zsófia and Kappéter, Ágnes and Kovács, Beáta and Péterfi, Zoltán},
	doi = {10.1556/OH.2014.30020},
	journal-iso = {ORV HETIL},
	journal = {ORVOSI HETILAP},
	volume = {155},
	unique-id = {2765530},
	issn = {0030-6002},
	abstract = {INTRODUCTION: During the past years a dramatic change has been observed in the epidemiology of Clostridium difficile infections. AIM: The aim of the authors was to investigate the possibility of the fecal microbiota transplantation and study differences, if any, in the success rate of the two different upper gastrointestinal tract method. METHOD: 100 ml of fecal microbiota solution was instilled via a nasoduodenal tube in 15 cases and a nasogastric tube in 15 cases. The authors defined the primary cure rate as the percentage of cases in which the symptoms disappeared without recurrence within 6 weeks after the first fecal microbiota transplantation, while secondary cure rate was calculated as the percentage of cases in which the symptoms resolved after the second fecal microbiota transplantation. RESULTS: It was found that fecal microbiota transplantation applied via the nasoduodenal tube resulted in a 100% primary cure rate. With the use of the nasogastric tube, the primary and secondary cure rate were 80% and 93.3%, respectively. Fecal microbiota transplantation via the upper gastrointestinal tract was found to have an overall primary cure rate of 90.0% and a secondary cure rate of 96.7%. CONCLUSIONS: Fecal microbiota transplantation proved to be very effective, particularly in recurrent infections and cases where conventional treatment failed. Orv. Hetil., 2014, 155(44), 1758-1762.},
	year = {2014},
	eissn = {1788-6120},
	pages = {1758-1762},
	orcid-numbers = {Vincze, Áron/0000-0003-2217-7686; Péterfi, Zoltán/0000-0001-9658-153X}
}

@article{MTMT:3004097,
	title = {Investigations on virulence phenotypes in asymptomatic bacteriuria Escherichia coli isolates},
	url = {https://m2.mtmt.hu/api/publication/3004097},
	author = {Kovács, Beáta and Rózsai, B and Dorn, Á and Kovács, J and Kerényi, Mónika and Melegh, Sz and Emődy, L},
	journal-iso = {ACTA MICROBIOL IMMUNOL HUNG},
	journal = {ACTA MICROBIOLOGICA ET IMMUNOLOGICA HUNGARICA},
	volume = {60},
	unique-id = {3004097},
	issn = {1217-8950},
	year = {2013},
	eissn = {1588-2640},
	pages = {36-36},
	orcid-numbers = {Kerényi, Mónika/0000-0002-5767-9662}
}

@misc{MTMT:3004112,
	title = {Limited expression of virulence traits in asymptomatic bacteriuria},
	url = {https://m2.mtmt.hu/api/publication/3004112},
	author = {Kovács, Beáta and Rózsai, B and Dorn, Á and Kovács, J and Kerényi, Mónika and Melegh, Sz and Emődy, L},
	unique-id = {3004112},
	year = {2012},
	orcid-numbers = {Kerényi, Mónika/0000-0002-5767-9662}
}

@misc{MTMT:30678404,
	title = {VRAM lebeny alkalmazása T4 stadiumú rectalis adenocarcinoma exstirpatioja utáni reconstructió céljából.. Magyar Sebész Társaság Coloproctológiai Szekció 2011. évi Kongresszusa, Hajdúszoboszló,2011.február 24-26.},
	url = {https://m2.mtmt.hu/api/publication/30678404},
	author = {Bognár, Gábor and István, Gábor and Lóderer, Zoltán and Barabás, Loránd and Kovács, Beáta and Novák, András and Ágoston, Emese Irma and Ledniczky, György and Ondrejka, Pál},
	unique-id = {30678404},
	year = {2011},
	orcid-numbers = {Bognár, Gábor/0000-0003-2135-9787; Lóderer, Zoltán/0000-0002-5458-2443; Barabás, Loránd/0000-0001-7246-2739; Ágoston, Emese Irma/0000-0001-9290-9630; Ledniczky, György/0000-0001-8178-8845; Ondrejka, Pál/0000-0001-6904-2098}
}